MetaCap

Bausch + Lomb Corporation (BLCO)

NYSE: BLCOHealth CareOphthalmic GoodsUSD

19.38-1.31 (-6.33%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

BLCO stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$0.32
52-week range
14.65 – 21.40
Day range
19.30 – 20.50
Volume / Avg
871.55K / 660.67K
Beta
—

52-week range

$14.65$21.40

BLCO stock today

Shares of Bausch + Lomb (BLCO) finished lower on Nov 20 at $19.38, a drop of 6.33% or $1.31 per share, versus the S&P 500's 3.70% decline. At this level, BLCO sits in the middle of its 52-week range of $14.65 to $21.40: 9.4% below the high, set on Nov 10, 2026 and 32.3% above the low. BLCO is up 13.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 28.6%.

Bausch + Lomb has posted a net loss over the last twelve months (EPS of -$0.32), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Bausch + Lomb

Company profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing.

Industry
Ophthalmic Goods
CEO
Mr. Thomas J. Appio
Headquarters
Vaughan, ON
Employees
13,000
IPO year
2022
Website
bausch.com

Financial highlights

Full financials

In fiscal 2025, Bausch + Lomb generated $5.10 billion in revenue, up 6.5% from fiscal 2024, its 5th consecutive year of revenue growth. Bausch + Lomb reported a net loss of $360.0 million, compared with a loss of $317.0 million a year earlier. Operating margin was 2.2%.

Bausch + Lomb annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$5.10B$4.79B$4.15B$3.77B$3.77B
Growth+6.47%+15.56%+10.03%+0.08%+10.35%
Net income$-360.00M$-317.00M$-260.00M$6.00M$182.00M
EPS (diluted)$-1.02$-0.90$-0.74$0.02$0.52

Analyst forecast

Forecast

Consensus (15 analysts)

buy

Avg. price target

$21.93+13.16%

  • Strong buy 2
  • Buy 4
  • Hold 8
  • Sell 0
  • Strong sell 1

Target range

Low $18.00High $27.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 28, 2026
EPS actual vs est.
$0.09 vs $0.21
Surprise
-57.14%

BLCO news

All BLCO news

Bausch + Lomb peers

Health Care sector
BLCO peer companies
CompanyPrice% ChgMarket capCompare
WRBYWarby Parker Inc. Class A23.12-4.19%$2.87Bvs BLCO
COOThe Cooper Companies Inc.58.88-2.40%$11.20Bvs BLCO
EYENational Vision Holdings Inc.16.72-1.70%$1.31Bvs BLCO
STAASTAAR Surgical Company24.22-3.24%$1.22Bvs BLCO
RXSTRxSight Inc.4.47-3.04%$187.42Mvs BLCO
LUCYInnovative Eyewear Inc.0.7025-0.07%$6.12Mvs BLCO
ALCAlcon Inc.74.31-0.26%$35.70Bvs BLCO

Indexes, lists and sector

Bausch + Lomb stock FAQ

What is Bausch + Lomb's stock price today?

BLCO last traded at $19.38 as of Nov 20, 4:00 PM EST, down 6.33% on the day. Prices are delayed at least 15 minutes.

Who is Bausch + Lomb's CEO?

Mr. Thomas J. Appio is the chief executive officer of Bausch + Lomb Corporation, which has about 13,000 employees.

What is the BLCO 52-week high?

The 52-week high for BLCO is $21.40 and the 52-week low is $14.65. The stock is currently 9.4% below its high.

Compare BLCO